aTyr Pharma (NASDAQ:LIFE)‘s stock had its “market perform” rating reaffirmed by William Blair in a research report issued on Tuesday. William Blair also issued estimates for aTyr Pharma’s FY2020 earnings at ($0.99) EPS.

Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine raised aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $1.01.

Shares of NASDAQ:LIFE opened at $0.51 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.38 and a quick ratio of 5.38. The stock has a market cap of $15.79 million, a P/E ratio of -0.44 and a beta of 2.41. aTyr Pharma has a 12-month low of $0.38 and a 12-month high of $2.90.

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Monday, March 25th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC raised its position in aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,107,025 shares of the biotechnology company’s stock after acquiring an additional 573,164 shares during the quarter. Renaissance Technologies LLC owned approximately 3.71% of aTyr Pharma worth $899,000 as of its most recent SEC filing. 35.28% of the stock is owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Recommended Story: Asset Allocation Models, Which is Right For You?

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.